ZJ 43

• Supplier: Tocris Bioscience
• Catalog: 3085
• Prices: $129.00, $279.00
• Sizes: 1 mg, 10 mg
• Function Type: Inhibitor
• Cas Number: 723331-20-2
• Chemical Name: N-[[[(1S)-1-Carboxy-3-methylbutyl]amino]carbonyl]-L-glutamicacid
• Formula: C12H20N2O7
• Molecular Weight: 304.3
• Description: Potent inhibitor of glutamate carboxypeptidase II and III (GCP II and III/NAAG peptidase/NAALADase) (K i values are 0.8 and 23 nM respectively) that inhibits the hydrolysis of NAAG (IC 50 = 2.4 nM) . Does not directly interact with NMDA or metabotropic glutamate receptors. Reduces neuronal degeneration in a rat model of traumatic brain injury (TBI) and reduces locomotor activity in the PCP-model of schizophrenia.

Product References

NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the - NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the

Olszewski RT, Bukhari N, Zhou J, Kozikowski AP, Wroblewski JT, Shamimi-Noori S, Wroblewska B, Bzdega T, Vicini S, Barton FB, Neale JH. J Neurochem. 2004 May;89(4):876-85.

NAAG peptidase inhibitors and their potential for diagnosis and therapy. - NAAG peptidase inhibitors and their potential for diagnosis and therapy.

Zhou J, Neale JH, Pomper MG, Kozikowski AP. Nat Rev Drug Discov. 2005 Dec;4(12):1015-26.

Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is - Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is

Yamamoto T, Saito O, Aoe T, Bartolozzi A, Sarva J, Zhou J, Kozikowski A, Wroblewska B, Bzdega T, Neale JH. Eur J Neurosci. 2007 Jan;25(1):147-58.